+13.1%
GSK vs LCID
-79.4%
+92.5%
-22.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | LCID | Excess | Alpha |
|---|---|---|---|---|
| 1D | +5.0% | +11.6% | -6.6% | +4.4% |
| 7D | +4.9% | -1.2% | +6.1% | +4.9% |
| 30D | +9.9% | -19.2% | +29.1% | +10.8% |
| 3M | +0.2% | -56.7% | +56.8% | +4.1% |
| 6M | +2.3% | -49.6% | +52.0% | +4.8% |
| YTD | +7.1% | -68.1% | +75.2% | +12.6% |
| 1Y | +13.1% | -79.4% | +92.5% | +24.8% |
| All | +13.1% | -79.4% | +92.5% | +24.8% |
Cumulative growth
Daily Returns
Daily percentage return beside LCID.
Daily Out/Under-Performance
Portfolio return minus LCID return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × LCID return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded LCID wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling